Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
jPufnUrTSKcgNLaK
Listen
